CVAC CureVac
- 2.770
- +0.120+4.53%
- 2.840
- +0.070+2.53%
CureVac News
Express News | CureVac NV : Jefferies Cuts Target Price to $7 From $21
CureVac Full Year 2023 Earnings: Misses Expectations
Express News | CureVac NV : UBS Cuts Target Price to $14 From $18
Curevac's Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
Express News | CureVac Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $12 to $4
CureVac Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 60% Leerink Partners $12 → $4 Downgrades Outperform → Market Perform 04/05/2024 — Guggenheim R
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
Express News | CureVac NV : Leerink Partners Cuts Target Price to $4 From $12
Express News | CureVac NV : Leerink Partners Cuts to Market Perform From Outperform
Earnings Call Summary | CureVac(CVAC.US) Q4 2023 Earnings Conference
The following is a summary of the CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript:Financial Performance:CureVac reported solid cash position of €402.5 million at the end of 2023 and expects to ex
CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
CureVac Launches Study for H5N1 Influenza Vaccine
CureVac Names New Chief Business Officer
Analysts' Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and CureVac (CVAC)
CureVac Shares Touch All-Time Low After Germany Deal Ends, Redesign News
By Stephen Nakrosis Shares of biopharmaceutical company CureVac touched a new low on Wednesday following news the company, together with GSK, ended a pandemic agreement with Germany and will implemen
CureVac Begins Early Stage Portion of Investigational Vaccine Trial
CureVac (CVAC) said Wednesday it initiated the early stage portion of a broader study into an investigational flu vaccine developed with GSK (GSK). The phase 1 trial is part of a combined phase 1/2 st
CureVac Hires New Chief Business Officer
German biopharmaceutical company CureVac (5CV.F) named Thaminda Ramanayake its new chief business officer, effective June 1. Ramanayake recently served as Affini-T Therapeutics' business chief, accord
Express News | CureVac Shares Are Trading Lower After the Company Reported Q4 Financial Results and Provided Business Updates
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M
08:01 AM EDT, 04/24/2024 (MT Newswires) -- Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M
CureVac BV Reports Q4 Results
Analysis
Price Target
No Data
